Bispecific antibody News and Research

RSS

Research unveils bispecific antibodies for B-cell lymphoma treatment

A new research paper was published in Oncotarget's Volume 15 on April 12, 2024, entitled, "Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface."

16 Apr 2024

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor.

14 Feb 2024

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

In this Interview, Dr. Fang-Yi Chu talks to NewsMed about the role of transmembrane proteins in targeting oncology research.

From Sino Biological Inc. 23 Nov 2023

B-BiTE modality enhances anti-myeloma effects of clinically available antibodies

Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment.

16 Nov 2023

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

7 Nov 2023

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

28 Oct 2023

New kidney tissue model could help assess safety of immunotherapy drugs

A growing repertoire of cell and molecule-based immunotherapies is offering patients with indomitable cancers new hope by mobilizing their immune systems against tumor cells.

23 Aug 2023

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.

25 Apr 2023

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Researchers from The University of Texas MD Anderson Cancer Center have developed fully human bispecific antibodies, as revealed in a recent study. These antibodies can bind to two distinct epitopes of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and have demonstrated the ability to neutralize various strains of the virus, including the Omicron variant.

14 Mar 2023

Researchers develop innovative STAb therapy for a type of leukemia

Researchers of the Hospital Universitario 12 de Octubre in Madrid and the Josep Carreras Leukaemia Research Institute have developed a cell therapy for a type of leukemia which currently has very few treatment options.

16 Jan 2023

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

12 Dec 2022

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

A recent study identified neutralizing antibodies against conserved SARS-CoV-2 epitopes.

30 Nov 2022

Study demonstrates immuno-based strategies to explore the treatment and prevention of COVID-19

Millions have died due to COVID-19 infection, and millions more continue experiencing the chronic condition, Long COVID, which makes discovering practical, accessible, and powerful SARS-CoV-2 preventatives and COVID-19 treatments essential.

11 Nov 2022

Researchers identify therapies for multiple myeloma patients whose cancer relapses after CAR-T

Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.

4 Nov 2022

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.

1 Sep 2022

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

In a new study, researchers developed bispecific-antibodies (bsAbs) against SARS-CoV-2 Omicron sub-lineages.

12 Aug 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022